Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry — POL-TAVI

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 305-311

  Czerwińska Jelonkiewicz, Katarzyna ^a   Zembala, Marian ^b   Dąbrowski, Maciej ^a   Witkowski, Adam ^a   Ochała, Andrzej ^b   Kochman, Janusz ^c   Dudek, Dariusz ^d   Kübler, Piotr ^e   Jagielak, Dariusz ^f   Stępińska, Janina ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bleeding; Dual antiplatelet therapy; Transcatheter aortic valve implantation; Vascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANTICOAGULATION; AORTA PROSTHESIS; AORTA SURGERY; ARTICLE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTHESIS IMPLANTATION; RISK REDUCTION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSCATHETER AORTIC VALVE IMPLANTATION; AORTIC VALVE STENOSIS; BIOPROSTHESIS; HEART VALVE PROSTHESIS; MIDDLE AGED; POLAND; POSTOPERATIVE COMPLICATIONS; REGISTER; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ASPIRIN; BIOPROSTHESIS; FEMALE; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLAND; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RETROSPECTIVE STUDIES; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 85005952152     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.095     Document Type: Article

References (20)

1. [1] Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M.J., Baron-Esquivias, G., Baumgartner, H., et al. Guidelines on the management of valvular heart disease. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 33 (2012), 2451–2496.
2. [2] Di Mario, C., Eltchaninoff, H., Neil Moat, N., Goicolea, J., Ussia, G.P., Kala, P., et al. The 2011–12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention 8 (2013), 1362–1371.
3. [3] Pilgrim, T., Kalesan, B., Wenawester, P., Huber, C., Stortecky, S., Buellesfeld, L., et al. Predictors of clinical outcomes in patients with severe aortic stenosis undergoing TAVI: a multistate analysis. Circ. Cardiovasc. Interv. 5 (2012), 856–861.
4. [4] GY, L., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J.M., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35 (2014), 3155–3179.
5. [5] Kappetein, A.P., Head, S.J., Genereux, P., Piazza, N., van Mieghem, N.M., Blackstone, E.H., et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur. Heart J. 33 (2012), 2403–2418.
6. [6] Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345 (2001), 494–502.
7. [7] Andreotti, F., Rocca, B., Husted, S., Ajjan, R.A., ten Berg, J., Cattaneo, M., et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 36 (2015), 3238–3249.
8. [8] Aryal, M.R., Karmacharya, P., Pandit, A., Hakim, F., Pathak, R., Mainali, N.R., et al. Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Heart Lung Circ. 24 (2015), 185–192.
9. [9] Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298].
10. [10] Van Mieghem, N.M., van der Boon, R.M., Faqiri, E., Diletti, R., Schultz, C., van Genus, R.J., et al. Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. J. Am. Coll. Cardiol. Intv. 6 (2013), 867–875.
11. [11] Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
12. [12] Alexander, J.H., Lopes, R.D., Thomas, L., Alings, M., Atar, D., Aylward, P., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J. 35 (2014), 224–232.
13. [13] Fang, M.C., Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J. Interv. Card. Electrophysiol. 25 (2009), 19–23.
14. [14] Hutten, B.A., Lensing, A.W., Kraaijenhagen, R.A., Prins, M.H., Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 14 (1999), 303–312.
15. [15] Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146 (2007), 857–867.
16. [16] Eikelboom, J.W., Wallentin, L., Connolly, S.J., Ezekowitz, M., Healey, J.S., Oldgren, J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123 (2011), 2363–2372.
17. [17] Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365 (2011), 883–891.
18. [18] Connolly, S.J., Eikelboom, J., Joyner, C., et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364 (2011), 806–817.
19. [19] Dewilde, W., Oirbans, T., Verheugt, F., Kelder, J.C., De Smet, B.J., Herrman, J.P., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
20. [20] Hansen, M.L., Sorensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunso, J., Gdsboll, N., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170 (2010), 1433–1441.